Archive: Company News
Pan Cancer T Extends Seed Financing Round with Additional Funding from Existing Shareholders and New Investor Thuja Capital
– Expanded investor syndicate strengthens the company’s financial position and investor base
Pan Cancer T B.V., a biotech spin-off from the Erasmus MC dedicated to the discovery and development of novel TCR-T therapies against solid tumors, announced today the closing of an extended seed investment round. All current shareholders participated in the round, with Thuja Capital joining as a new investor. The undisclosed proceeds add to the initial seed capital financing announced earlier this year. The Company’s syndicate of experienced life science venture capital investors now includes Van Herk Ventures, Swanbridge Capital, and Thuja Capital as well as founding shareholder Erasmus MC.
MIKROGEN Expands Diagnostic Product Range with T-Track® SARS-CoV-2 Test for Assessing T-cell Mediated Immune Responses
Mikrogen GmbH, a company developing genetically manufactured in vitro diagnostics, today announced the expansion of its product portfolio with the introduction of its T-Track® SARS-CoV-2 test to determine T-cell mediated immune responses.
The new RT-qPCR-based T-Track® assays (T-Track® SARS-CoV-2) detect the mRNA expression of specific marker cytokines, which in addition to the reactivity of memory T-cells also detect the reactivity of in vivo activated effector T-cells, thereby achieving the highest possible sensitivity. The new technology can detect several cytokines simultaneously by PCR with comparative ease and therefore stands out from other available methods for determining T-cell activity.
Curexsys Appoints Christian Eckert as Chief Operating Officer
– Strengthened management team headed by Jörg Neermann as CEO
Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced the appointment of Christian Eckert, PhD, as Chief Operating Officer. He joins Curexsys´ recently expanded management board which consists of Jörg Neermann, PhD, Chief Executive Officer, and the Company´s co-founder Jens Gruber, PhD, Chief Scientific Officer.
ImmunOs Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)
– Preclinical data highlighting mode-of-action of lead program iosH2
ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced that the Company will present a scientific poster at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting (SITC) which will be held November 10-14, 2021, in Washington, DC, USA.